Mission statement · Company scope
“Our mission is to overcome the limitations of cytokine therapies and checkpoint inhibitors, such as anti-CTLA-4, and make immunotherapies beyond anti-PD-1/PD-L1 treatments more accessible, efficacious and safe for patients with cancer.”
In use2024 – now1 sighting
First seenApr 2024Added
Last seenApr 2024Latest observation
Date created—Not published by the organization
Record
- Kind
- Mission
- Scope
- Company
- Style
- Problem–solution (primary) · Customer-centric · Democratization
- Leads with
- Problem
- Best for
- Climate & health · Service business
- Formula
- [Problem] shouldn’t [cost]. We [how].
- Tone
- Plain
- Length
- 31 words · reading grade 19.6
- Review status
- unreviewed · classifier rules-v0
- Quality score
- 0.74
- Record
- st_acfeb93da2caf8b3
- Classification confidence
- 0.67
Sources1 sighting
SEC
SEC EDGAR filingsObserved 2024-04-01 · sec_sentence · 10-K · accession 0001558370-24-004530
View filing ↗0 to compareCompare